Why Some Autoimmune Diseases Strike Later in Life: New Clues from Aging T Cells

Type 1 diabetes strikes mainly in childhood and young adulthood. But other autoimmune diseases tell a different story. Chronic inflammatory demyelinating polyneuropathy (CIDP)—an autoimmune condition that damages nerve insulation—peaks in people aged 70 to 79. Scientists have long wondered: why do some autoimmune diseases favor the young while others target the old?

A new study published on bioRxiv offers a biological explanation. Researchers found that aging fundamentally reshapes how immune cells behave, making them both more damaging and harder to control.

The immune cells at the center of this research are CD4+ T cells, which normally help coordinate immune responses. In younger people, these cells divide, fight infection, and then die off when no longer needed. But as people age, some CD4+ T cells develop a state called 'senescence.'

Senescent cells are stuck in a strange limbo: they stop dividing but refuse to die. Instead, they accumulate and release inflammatory chemicals—a pattern researchers call a 'senescence-associated secretory phenotype' (SASP). The study found that CIDP patients have more of these aging, inflammatory CD4+ T cells than healthy people, suggesting these cells play a role in disease.

The researchers tested two experimental approaches in mice with CIDP-like disease. The first was fisetin, a compound designed to clear senescent cells from the body. The second was ruxolitinib, a drug that dampens the inflammatory signals these aging cells release. Both reduced the disease's severity in animals.

These findings remain preliminary and were tested only in mice. They do not constitute medical recommendations, but they point toward a new understanding: age-related changes in immune cells may drive certain autoimmune diseases, and targeting these changes might someday help prevent or treat them.

This work highlights an important truth: autoimmune disease is not one condition but many, shaped by different biological processes at different ages. Understanding why Type 1 diabetes appears early and CIDP appears late requires understanding how aging reshapes the immune system itself.

Researchers are now working to confirm whether the same senescent immune cell mechanism contributes to other age-related autoimmune diseases, and whether treatments that work in mice might be safe and effective in people.

Source: bioRxiv : the preprint server for biology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.